Year Published
- 2008 (0)
- 2009 (1) Apply 2009 filter
- (-) Remove 2010 filter 2010
- 2011 (3) Apply 2011 filter
- 2012 (3) Apply 2012 filter
- 2013 (1) Apply 2013 filter
- 2014 (1) Apply 2014 filter
- 2015 (0)
- 2016 (4) Apply 2016 filter
- 2017 (8) Apply 2017 filter
- (-) Remove 2018 filter 2018
- 2019 (1) Apply 2019 filter
- 2020 (0)
- 2021 (1) Apply 2021 filter
Research Topics
Populations
- Countries/Governments (0)
- Rural Populations (0)
- Smallholder Farmers (0)
- Women (1) Apply Women filter
Types of Research
- Data Analysis (0)
- Literature Review (2) Apply Literature Review filter
- Portfolio Review (0)
- Research Brief (0)
Geography
- (-) Remove East Africa Region and Selected Countries filter East Africa Region and Selected Countries
- (-) Remove Global filter Global
- South Asia Region and Selected Countries (0)
- Southern Africa Region and Selected Countries (0)
- Sub-Saharan Africa (8) Apply Sub-Saharan Africa filter
- West Africa Region and Selected Countries (0)
Dataset
- ASTI (0)
- FAOSTAT (0)
- Farmer First (0)
- LSMS & LSMS-ISA (0)
- Other Datasets (0)
Current search
- (-) Remove East Africa Region and Selected Countries filter East Africa Region and Selected Countries
- (-) Remove Environment & Climate Change filter Environment & Climate Change
- (-) Remove Education & Training filter Education & Training
- (-) Remove Gender filter Gender
- (-) Remove 2010 filter 2010
- (-) Remove Global & Regional Public Goods filter Global & Regional Public Goods
- (-) Remove 2018 filter 2018
- (-) Remove Global filter Global
The private sector is the primary investor in health research and development (R&D) worldwide, with investment annual investment exceeding $150 billion, although only an estimated $5.9 billion is focused on diseases that primarily affect low and middle-income countries (LMICs) (West et al., 2017b). Pharmaceutical companies are the largest source of private spending on global health R&D focused on LMICs, providing $5.6 billion of the $5.9 billion in total private global health R&D per year. This report draws on 10-K forms filed by Pharmaceutical companies with the U.S. Securities and Exchange Commission (SEC) in the year 2016 to examine the evidence for five specific disincentives to private sector investment in drugs, vaccines and therapeutics for global health R&D: scientific uncertainty, weak policy environments, limited revenues and market uncertainty, high fixed costs for research and manufacturing, and imperfect markets. 10-K reports follow a standard format, including a business section and a risk section which include information on financial performance, investment options, lines of research, promising acquisitions and risk factors (scientific, market, and regulatory). As a result, these filings provide a valuable source of information for analyzing how private companies discuss risks and challenges as well as opportunities associated with global health R&D targeting LMICs.
Contract farming (CF) is an arrangement between farmers and a processing or marketing firm for the production and supply of agricultural products, often at predetermined prices. This literature review builds on EPAR's review of smallholder contract farming in Sub-Saharan Africa (SSA) and South Asia (EPAR Technical Report #60) by specifically examining the evidence on impacts and potential benefits of contract farming for women in SSA. Key takeaways suggest women’s direct participation in contract farming is limited, with limited access to land and control over the allocation of labor and cash resources key constraints hindering women’s ability to benefit from CF. Further, we find that the impact of contract farming on women is often mediated by their relative bargaining power within the household.